"GTP is at the forefront of medical science and developing innovative therapies for patients with rare conditions and few therapeutic options. Engaging with global regulatory authorities is essential to the advancement of gene therapy products through clinical evaluation, and to providing a pathway to future treatments.”
Antony Appleyard serves as the Executive Director of Regulatory Affairs at the Gene Therapy Program. In this role, Antony leads the Regulatory Affairs department which is responsible for regulatory strategy and global health authority interactions. Antony has more than 20 years of experience in research, clinical development, and manufacturing. Previously, Antony was a consultant for nine years at Diamond Pharma Services, where he led a multidisciplinary group providing regulatory support to clients developing cell and gene therapy products.
Earlier in his career, Antony was engaged in antibacterial development at Novacta Biosystems, and he was responsible for the technical transfer of antibody manufacturing processes at a subsidiary of Abbott Laboratories. Antony holds a degree in Chemistry and a PhD in Biochemistry from the University of Leeds, and he carried out post-doctoral research in the Departments of Chemistry and Biochemistry at the University of Cambridge. He is a Fellow of the Royal Society of Chemistry, a Chartered Chemist, and a member of TOPRA.